 CHICAGO--BUSINESS WIRE--Xeris Pharmaceuticals, Inc. Nasdaq: XERS, a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on October 1, 2021, the Compensation Committee of Xeris Board of Directors granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employees under Xeris Inducement Equity Plan. Xeris Inducement Equity Plan is us 